Search research articles
Contact Us
Filters
Showing results (1-10 of 8) with videos related to
Page
of 1
Sort By:
Expert Opinion on Biological Therapy
|
October 20, 2018
Wide variation in the use and understanding of therapeutic drug monitoring for anti-TNF agents in inflammatory bowel disease: an inexact science?
Mark A Samaan, Zehra Arkir, Tariq Ahmad, et al.
JMIR Research Protocols
|
October 21, 2018
The Clinical and Cost-Effectiveness of 4 Enzyme-Linked Immunosorbent Assay Kits for Monitoring Infliximab in Crohn Disease Patients: Protocol for a Validation Study
Thomas Langford, Zehra Arkir, Anastasia Chalkidou, et al.
The Journal of Investigative Dermatology
|
March 8, 2023
Real-World Implementation and Outcomes of Adalimumab Therapeutic Drug Monitoring in Psoriasis: A National Specialized Center Experience
Antony Raharja, Zehra Arkir, Giulia Rinaldi, et al.
Alimentary Pharmacology & Therapeutics
|
June 8, 2020
Therapeutic thresholds for golimumab serum concentrations during induction and maintenance therapy in ulcerative colitis: results from the GO-LEVEL study
Mark A Samaan, Georgina Cunningham, Aravind Gokul Tamilarasan, et al.
Alimentary Pharmacology & Therapeutics
|
July 5, 2021
An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switch
Raphael P Luber, Rhona O'Neill, Sukhpreet Singh, et al.
The Journal of Investigative Dermatology
|
February 21, 2025
Personalizing Biologic Therapy in Psoriasis: Development, Validation, and User Testing of a Precision-Dosing Dashboard
Charlotte M Thomas, David Baudry, Zehra Arkir, et al.
British Journal of Clinical Pharmacology
|
February 15, 2026
Pharmacokinetic-pharmacodynamic modelling of risankizumab using chronic plaque psoriasis real-world data
Charlotte M Thomas, Jessica Ruoheng Wei, David Baudry, et al.
Journal of Crohn'S & Colitis
|
September 2, 2021
Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients
Neil Chanchlani, Simeng Lin, Desmond Chee, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 8) with videos related to
Sort By:
Page
of 1
Expert Opinion on Biological Therapy
|
October 20, 2018
Wide variation in the use and understanding of therapeutic drug monitoring for anti-TNF agents in inflammatory bowel disease: an inexact science?
Mark A Samaan, Zehra Arkir, Tariq Ahmad, et al.
JMIR Research Protocols
|
October 21, 2018
The Clinical and Cost-Effectiveness of 4 Enzyme-Linked Immunosorbent Assay Kits for Monitoring Infliximab in Crohn Disease Patients: Protocol for a Validation Study
Thomas Langford, Zehra Arkir, Anastasia Chalkidou, et al.
The Journal of Investigative Dermatology
|
March 8, 2023
Real-World Implementation and Outcomes of Adalimumab Therapeutic Drug Monitoring in Psoriasis: A National Specialized Center Experience
Antony Raharja, Zehra Arkir, Giulia Rinaldi, et al.
Alimentary Pharmacology & Therapeutics
|
June 8, 2020
Therapeutic thresholds for golimumab serum concentrations during induction and maintenance therapy in ulcerative colitis: results from the GO-LEVEL study
Mark A Samaan, Georgina Cunningham, Aravind Gokul Tamilarasan, et al.
Alimentary Pharmacology & Therapeutics
|
July 5, 2021
An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switch
Raphael P Luber, Rhona O'Neill, Sukhpreet Singh, et al.
The Journal of Investigative Dermatology
|
February 21, 2025
Personalizing Biologic Therapy in Psoriasis: Development, Validation, and User Testing of a Precision-Dosing Dashboard
Charlotte M Thomas, David Baudry, Zehra Arkir, et al.
British Journal of Clinical Pharmacology
|
February 15, 2026
Pharmacokinetic-pharmacodynamic modelling of risankizumab using chronic plaque psoriasis real-world data
Charlotte M Thomas, Jessica Ruoheng Wei, David Baudry, et al.
Journal of Crohn'S & Colitis
|
September 2, 2021
Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients
Neil Chanchlani, Simeng Lin, Desmond Chee, et al.
Page
of 1